期刊
JOURNAL OF NEURO-ONCOLOGY
卷 91, 期 2, 页码 127-139出版社
SPRINGER
DOI: 10.1007/s11060-008-9691-5
关键词
Malignant glioma; Immunotherapy; Dendritic cells; In vivo bioluminescence; Stereomicroscopy; Validation
资金
- Olivia Hendrickx Research Fund
- Institute for the Promotion of Innovation through Science and Technology in Flanders
- MoSAIC Excellence
The value of bioluminescence imaging (BLI) for experimental cancer models has become firmly established. We applied BLI to the GL261 glioma model in the context of dendritic cell (DC) immunotherapy. Initial validation revealed robust linear correlations between in vivo, ex vivo and in vitro luciferase activity measurements. Ex vivo BLI demonstrated midline crossing and leakage of tumor cells. Orthotopically challenged mice followed with BLI showed an initial adaptation phase, after which imaging data correlated linearly with stereologically determined tumor dimensions. Transition from healthy to moribund state corresponded with an increasing in vivo flux but the onset of neurological deficit was clearly delayed compared to the onset of in vivo flux increase. BLI was implemented in prophylactic immunotherapy and imaging data were prognostic for therapy outcome. Three distinct response patterns were detected. Our data underscore the feasibility of in vivo BLI in an experimental immunotherapeutic setting in the GL261 glioma model.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据